The story
On December 2, 2020, the United Kingdom became the first country to authorize a COVID-19 vaccine developed by the German company BioNTech and its American partner Pfizer, and on December 8, 90-year-old Margaret Keenan in Coventry became the first person to receive it outside a trial. The United States authorized it days later, followed by a second vaccine from the American company Moderna. Both were mRNA vaccines, a kind never before approved for use, and in large trials each cut the risk of symptomatic COVID-19 by about 95 percent. Fewer than eleven months had passed since the virus's genetic code was first published.
mRNA, or messenger RNA, is the molecule cells use to carry a gene's instructions to the protein-making machinery. Instead of injecting a weakened virus or a piece of one, an mRNA vaccine delivers the instructions for one viral protein, here the 'spike' the coronavirus uses to enter cells. The body's own cells make the spike for a short time, the immune system learns to recognize it, and the mRNA is quickly broken down. The idea was decades old but had serious problems: injected mRNA triggered harmful inflammation and was destroyed before doing its job. In 2005 Katalin Karikó and Drew Weissman at the University of Pennsylvania showed that swapping one of mRNA's chemical letters for a modified version let it slip past the immune alarms. Tiny fat bubbles called lipid nanoparticles, refined over years, protected the mRNA and carried it into cells.
Speed came from the technology's flexibility. Once Chinese scientists posted the virus's genome in January 2020, Moderna and BioNTech could design their vaccines on computers within days, since changing the target means changing the mRNA sequence rather than growing a new virus. Earlier research on related coronaviruses showed how to lock the spike protein in its most recognizable shape. Large government funding, including the U.S. Operation Warp Speed, let companies run trial phases in parallel and manufacture doses before approval.
Billions of doses followed, though early supply went mostly to rich countries, and the Pfizer shot initially needed ultra-cold freezers. Karikó and Weissman won the 2023 Nobel Prize in Physiology or Medicine.
Why it mattered
- Vaccination campaigns in 2021 are estimated to have prevented millions of COVID-19 deaths.
- mRNA became a platform for vaccines and treatments against flu, RSV, cancer and other diseases.
- Vaccine development timelines were permanently shortened, changing how the world prepares for future pandemics.
- Debates over vaccine mandates and misinformation became a lasting feature of politics in many countries.
Sources
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…